ZA200500411B - Modafinil polymorphic forms - Google Patents

Modafinil polymorphic forms

Info

Publication number
ZA200500411B
ZA200500411B ZA2005/00411A ZA200500411A ZA200500411B ZA 200500411 B ZA200500411 B ZA 200500411B ZA 2005/00411 A ZA2005/00411 A ZA 2005/00411A ZA 200500411 A ZA200500411 A ZA 200500411A ZA 200500411 B ZA200500411 B ZA 200500411B
Authority
ZA
South Africa
Prior art keywords
polymorphic forms
modafinil polymorphic
modafinil
forms
polymorphic
Prior art date
Application number
ZA2005/00411A
Other languages
English (en)
Inventor
Frydman Armand
Coquerel Gerard
Broquaire Michel
Courvoisier Laurent
Mallet Franck
Original Assignee
Teva Sente
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Sente filed Critical Teva Sente
Publication of ZA200500411B publication Critical patent/ZA200500411B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA2005/00411A 2002-08-09 2005-01-17 Modafinil polymorphic forms ZA200500411B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40206402P 2002-08-09 2002-08-09
US10/635,445 US6992219B2 (en) 2002-08-09 2003-08-07 Modafinil polymorphic forms
PCT/IB2003/003215 WO2004014846A1 (en) 2002-08-09 2003-08-08 Modafinil polymorphic forms

Publications (1)

Publication Number Publication Date
ZA200500411B true ZA200500411B (en) 2006-07-26

Family

ID=31720568

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2005/00411A ZA200500411B (en) 2002-08-09 2005-01-17 Modafinil polymorphic forms

Country Status (11)

Country Link
US (3) US6992219B2 (https=)
EP (2) EP1575915A1 (https=)
JP (2) JP4718177B2 (https=)
CN (3) CN100506790C (https=)
AU (1) AU2003253128B2 (https=)
CA (4) CA2804385A1 (https=)
IL (3) IL166301A (https=)
MX (1) MXPA05001506A (https=)
NZ (1) NZ537840A (https=)
WO (1) WO2004014846A1 (https=)
ZA (1) ZA200500411B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003529A3 (cs) 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
JP4498679B2 (ja) * 2001-03-27 2010-07-07 大日本住友製薬株式会社 結晶性イソキサゾール誘導体およびその医薬製剤
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US7244865B2 (en) * 2003-02-24 2007-07-17 Mallinckrodt Inc. Process for preparing benzhydrylthioacetamide
WO2004083183A1 (en) * 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US7504516B2 (en) * 2003-03-27 2009-03-17 Hetero Drugs Limited Crystalline forms of candesartan cilexetil
AU2003230195A1 (en) * 2003-04-02 2004-10-25 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US7560560B2 (en) * 2003-04-16 2009-07-14 Hetero Drugs Limited Crystalline forms of donepezil hydrochloride
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
PT1673370E (pt) 2003-10-16 2009-11-05 Symed Labs Ltd Forma cristalina de linezolida
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
WO2005099822A2 (en) * 2004-04-13 2005-10-27 Cephalon, Inc. Reduction of drug / drug interactions with modafinil
WO2005099353A2 (en) * 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
EP1755388B1 (en) * 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US20060235008A1 (en) 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
CA2614777C (en) * 2005-07-21 2012-04-17 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
US7518019B2 (en) * 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
EP2056811B8 (en) * 2006-08-14 2018-03-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
US8791046B2 (en) 2006-11-10 2014-07-29 Basf Se Crystalline modification of fipronil
JP5931322B2 (ja) 2006-11-10 2016-06-08 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ フィプロニルの結晶変態
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
US20100234468A1 (en) * 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10596103B2 (en) 2013-12-11 2020-03-24 Merek Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
EP4210709B1 (en) * 2020-09-14 2025-10-29 Pharma Cinq, LLC 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520812A (en) * 1975-10-02 1978-08-09 Lafon Labor Benzhydrylsulphinyl derivatives
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2697162B1 (fr) 1992-10-23 1995-01-13 Lafon Labor Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux.
FR2706767B1 (https=) * 1993-06-22 1995-09-08 Lafon Labor
FR2707637B1 (fr) 1993-06-30 1995-10-06 Lafon Labor Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique.
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
FR2771004B1 (fr) * 1997-11-19 2000-02-18 Inst Curie Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IL128989A0 (en) 1999-03-15 2000-02-17 Popov Sergey Safety trocar assembly
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2804322B1 (fr) * 2000-01-31 2002-04-19 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
CZ2003529A3 (cs) * 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CZ2004446A3 (cs) 2001-09-07 2005-01-12 Teva Pharmaceutical Industries Ltd. Krystalické formy valaciklovir hydrochloridu
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040242698A1 (en) 2003-05-13 2004-12-02 Cephalon Inc. Analeptic and antidepressant combinations
US20040229941A1 (en) 2003-05-13 2004-11-18 Cephalon, Inc. Analeptic and antidepressant combinations
AR045423A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Combinaciones de analiticos y antidepresivos
AR045314A1 (es) 2003-05-13 2005-10-26 Cephalon Inc Composiciones farmaceuticas de analepticos y antidepresivos
US20040229943A1 (en) 2003-05-16 2004-11-18 Cephalon Inc Analeptic and drug combinations
ES2330321T3 (es) 2003-05-16 2009-12-09 Cephalon France Procedimiento de sintesis de modafinilo.

Also Published As

Publication number Publication date
US20040102523A1 (en) 2004-05-27
AU2003253128A1 (en) 2004-02-25
JP5307106B2 (ja) 2013-10-02
US7405323B2 (en) 2008-07-29
CA2746788A1 (en) 2004-02-19
JP2011046730A (ja) 2011-03-10
CN102875429A (zh) 2013-01-16
US20080153918A1 (en) 2008-06-26
US7649020B2 (en) 2010-01-19
CA2804385A1 (en) 2004-02-19
IL166301A (en) 2011-06-30
EP2402311A1 (en) 2012-01-04
CA2746788C (en) 2013-04-09
IL209965A0 (en) 2011-07-31
IL166301A0 (en) 2006-01-15
CA2494010C (en) 2011-10-18
CA2494010A1 (en) 2004-02-19
NZ537840A (en) 2007-01-26
CN100506790C (zh) 2009-07-01
CA2840721C (en) 2015-06-16
CA2840721A1 (en) 2004-02-19
CN102875430A (zh) 2013-01-16
IL209966A (en) 2013-02-28
CN1675177A (zh) 2005-09-28
EP1575915A1 (en) 2005-09-21
MXPA05001506A (es) 2005-08-16
WO2004014846A1 (en) 2004-02-19
CN102875429B (zh) 2014-12-10
JP2005535698A (ja) 2005-11-24
US6992219B2 (en) 2006-01-31
US20060252835A1 (en) 2006-11-09
AU2003253128B2 (en) 2009-01-29
IL209966A0 (en) 2011-07-31
JP4718177B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
IL209965A0 (en) Modafinil polymorphic forms
IL166084A0 (en) Novel benzodioxoles
PL371678A1 (en) Novel pyridin- and pyrimidin-derivatives
PL373598A1 (en) Novel benzonaphthyridines
IL163529A0 (en) Novel spinosyn-producing polyketidesynthases
GB0206169D0 (en) Rhenium compounds
AU2003209667A8 (en) Bicalutamide polymorphs
GB0208928D0 (en) Methods
GB0225750D0 (en) Wiffs away
GB0220045D0 (en) Methods
IL166308A0 (en) Polymorphic forms of nateglinide
AU2003264722A8 (en) Methods
GB0221711D0 (en) Methods
GB0202213D0 (en) Methods
GB0204967D0 (en) Methods
AU2003275480A8 (en) Compounds
GB0213580D0 (en) Methods
GB0222276D0 (en) Methods
GB0229743D0 (en) Novel benzoxazocines
GB0213579D0 (en) Methods
GB0200526D0 (en) Methods
AU154296S (en) Section
EP1463794A4 (en) IMIDAZOLINE QUATERNARY COMPOUNDS
GB0224928D0 (en) Polymorphism
GB0201794D0 (en) Pharmaceutically-useful compounds